In the title compound, C18H17BrN2O2, which is a potential human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor, the pyrrolidine ring exhibits an envelope conformation. In the crystal structure, intermolecular N—H⋯O hydrogen bonds [N⋯O = 2.861 (3) Å] link the molecules into centrosymmetric dimers.